New Study Published In Medical Journal Calls COVID-19 Spike Acute-On-Chronic Health Emergency, A ‘Syndemic’ Perfect Storm Of Pain, Including Acute Lower Back Pain For Younger People; Electromedical Technologies, Inc. (OTCQB: EMED) Offers Electrotherapy And Bioelectronic Back And Leg Treatments Without Opioid-Addicting Pain Killer Drugs
The Global Burden of Disease (GBD) Study published in The Lancet medical journal of London calls the new spike in COVID-19 globally a perfect storm of acute-on-chronic health emergency, launching worldwide attacks on lungs, heart and kidneys causing possible fatal high blood pressure, high cholesterol and, in people between 10-49 years of age, acute lower back pain. The impact of this COVID-19 virus is unprecedented. Electromedical Technologies, Inc. (OTCQB: EMED) can help ease lower back pain through Electrotherapy And Bioelectronic Back and leg treatments without opioid-addicting pain killer drugs.
The chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT), Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM). GlaxoSmithKline (NYSE: GSK), Abbott Laboratories (NYSE: TBA), Eli Lilly (NYSE: LLY), Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).
New Study Published In Medical Journal Calls COVID-19 Spike Acute-On-Chronic Health Emergency, A ‘Syndemic’ Perfect Storm Of Pain Including Acute Lower Back Pain For Younger People; Electromedical Technologies, Inc. (OTCQB: EMED) Offers Electrotherapy And Bioelectronic Back And Leg Treatments Without Opioid-Addicting Pain Killer Drugs
Dr. Richard Horton, Editor-In-Chief of The Lancet, said, “COVID-19 is an acute-on-chronic health emergency. And the chronicity of the present crisis is being ignored at our future peril.” The study of COVID-19 and 204 countries included analysis of 87 risk factors.
COVID-19 OffersThe Perfect Recipe For More Chronic And Acute Pain
As the new spike is the perfect recipe for chronic and acute pain and acceleration of already-present diseases — such as high sugar levels in the blood, heart disease and kidney damage — non-invasive techniques to lower pain levels without the use of addictive opioid pain killers is vital. As medical institutions and professional associations such as Cleveland Clinic, National Institutes of Health (NIH) and the American Society of Anesthesiologists seek cures,treatments being sought include minimally-invasive neuro-stimulation, using electrical impulses to relieve back and leg pain. Electromedical Technologies, Inc. (OTCQB: EMED) offers Electrotherapy and Bioelectronic treatments through a line of non-invasive devices.
The American Society of Anesthesiologists Addresses Chronic Pain Management
The American Society of Anesthesiologists (ASA) believes that chronic pain management cannot wait for the COVID-19 pandemic to end — it is even more critical during stressful times, it finds. The newest spike, which has triggered renewed lockdowns in Europe and threatens more in U.S. hotspots, has physicians focused on in-person medical visits with patients suffering from chronic and acute pain. They seek treatments that reduce visits needed and offer long-lasting relief of pain for six months or more. New Study Published In Medical Journal Calls COVID-19 Spike Acute-On-Chronic Health Emergency, A ‘Syndemic’ Perfect Storm Of Pain Such As Acute Lower Back Pain For Younger People; Electromedical Technologies, Inc. (OTCQB: EMED) Offers Electrotherapy And Bioelectronic Back And Leg Treatments Without Opioid-Addicting Pain Killer Drugs.
New COVID-19 Spike Means More Acute And Chronic Pain, Possible Future Lockdowns
Electromedical Technologies, Inc. (OTCQB: EMED) Offers Chronic And Acute Pain Relief Through its Devices: the FDA-cleared WellnessPro Plus™ and anticipated for 2021 the WellnessPro® Pod. Electromedical Technologies, Inc. (OTCQB: EMED) has developed devices such as the FDA-cleared WellnessPro Plus™ and anticipated for 2021 the WellnessPro® Pod. These are non-invasive devices which avoid side-effects such as opioid addiction. They deliver to sufferers of chronic and acute pain relief through electrotherapy and bioelectronic non-invasive treatments offered by these devices.
COVID-19 Makes Ill Patients Even More Vulnerable
Electromedical Technologies, Inc. (OTCQB: EMED) is a leader in the field of addressing acute and chronic pain and sees itself at the forefront of future medicine. Opioid addiction from pain-killer pharmaceuticals, is only accelerated by COVID-19. The global pandemic causes patients with chronic pain to limit or avoid physical physician visits, postpone surgical treatments and limit out-of-home mobility — making patients even more vulnerable.
Collaboration With Universities And Schools, Certification Training
StreetInsider.com says electrotherapy and bioelectronic treatments can be helpful in treating chronic and acute pain without addictive drugs. It terms the Electromedical Technologies, Inc. (OTCQB: EMED) devices as in the forefront of the future of medicine. Matthew Wolfson, founder and CEO of EMED, has pursued collaboration with universities and schools on chronic pain research and certification training that offers a ‘Bioelectronics Therapist and Master Device Technician.’
NIH Raises The Stakes On Chronic Pain And Treatments
The National Institutes Of Health (NIH) has raised the stakes on chronic pain and possible treatment that leads to opioid addiction through pain killer pharmaceuticals. NIH awarded its ‘Pain Research Center’ additional funding through its Director’s Challenge Innovative Award program in 2020 as it seeks to focus research on chronic pain.
The NIH said, “Chronic pain affects millions of people, lacks effective treatments and and is a primary driver of opioid misuse disorders.” Cleveland Clinic, a prestigious medical institution, is offering multi-disciplinary relief through its Cleveland Clinic-Martin Health pain management center in Florida. New Study Published In Medical Journal Calls COVID-19 Spike Acute-On-Chronic Health Emergency, A ‘Syndemic’ Perfect Storm Of Pain, Including Lower Back Pain For Younger People; Electromedical Technologies, Inc. (OTCQB: EMED) Offers Electrotherapy And Bioelectronic Back And Leg Treatments Without Opioid-Addicting Pain Killer Drugs.
Pain Treatment Market Seen Reaching $151.7 Billion Globally By 2030
A new research study by The Centers For Disease Control And Prevention (CDC) finds that greater than 20% of American adults suffer from chronic pain and high-impact chronic pain, sometimes resulting in opioid dependence. The COVID-19 pandemic, a recent study by Prescient & Strategic Intelligence reports, only exacerbates these numbers and helps drive the chronic pain treatment market globally by a 6.5% CAGR rate to $151.7 Billion by 2030 from $77.8 Billion in 2019.
EMED Plans To Study The Effects Of Electro-Modulation On The Human Body
Electromedical Technologies, Inc. (OTCQB: EMED) offers a growing line of devices that deliver electrotherapy treatment for chronic and acute pain. Next year, the Company anticipates bringing to market its WellnessPro® Pod. The Company is collaborating with numerous universities and schools to research the field of bioelectronics. It is seeking to develop a program to study the effects of electro-modulation on the human body, especially cell signaling and virus assembly and immune responses.
Source: Stock Market Press
Join Stock Market Press’ newsletter for the latest in IPO, market commentary and company profiles.
Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.
Contact:
Stock Market Press
110 Wall St.
New York, NY 10005 info@stockmarketpress.com Safe Harbor Statement:
Statements in this news release may be ”forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.
See Stock Market Press disclaimer: https://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press
